Vivos Therapeutics, Inc. (VVOS) shareholders
Close on Nov 17, 2026Market cap $1.60MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Michael C. Skaff Joint filing with SP Manager LLC (19.90%), V-Co Investors 3 LLC (9.70%) and 1 more | 2,783,102 | 19.90% | 13D (active) | Jun 30, 2026 |
| SP Manager LLC Joint filing with Michael C. Skaff (19.90%), V-Co Investors 2 LLC (12.30%) and 1 more | 1,342,498 | 19.90% | 13D (active) | Jun 9, 2025 |
| Dawei Luo | 572,016 | 8.52% | 13G (passive) | Jul 8, 2025 |
| Michael Skaff Joint filing with V-CO Investors LLC (9.90%), SP Manager LLC (9.90%) | 514,498 | 9.90% | 13G (passive) | Dec 17, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VVOS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 85,001 | 0.42% | $38.63K | −10,542 | 0.00% |
| IHT Wealth Management, LLC | 76,736 | 0.38% | $34.88K | +35,675 | 0.00% |
| Vanguard Capital Management LLC | 60,629 | 0.30% | $27.59K | −212,700 | 0.00% |
| Commonwealth Equity Services, LLC | 42,500 | 0.21% | $19.32K | – | 0.00% |
| UBS Group AG | 39,154 | 0.19% | $17.82K | +28,108 | 0.00% |
| B. Riley Wealth Advisors, Inc. | 38,066 | 0.19% | $18.77K | – | 0.00% |
| Centurion Wealth Management LLC | 35,684 | 0.18% | $16.22K | – | 0.00% |
| BlackRock, Inc. | 27,817 | 0.14% | $12.64K | – | 0.00% |
| State Street Corp | 24,922 | 0.12% | $11.33K | – | 0.00% |
| Sequoia Financial Advisors, LLC | 24,000 | 0.12% | $10.91K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 23,432 | 0.12% | $10.66K | −7,400 | 0.00% |
| Northern Trust Corp | 20,775 | 0.10% | $9.44K | +8,264 | 0.00% |
| Acorn Wealth Advisors, LLC | 14,776 | 0.07% | $6.72K | – | 0.00% |
| Susquehanna International Group, Llp | 10,075 | 0.05% | $4.58K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 5,211 | 0.03% | $2.37K | −2,177 | 0.00% |
| Osaic Holdings, Inc. | 1,143 | 0.01% | $516 | – | 0.00% |
| Signaturefd, LLC | 547 | 0.00% | $249 | – | 0.00% |
| Integrated Wealth Concepts LLC | 320 | 0.00% | $144 | New | 0.00% |
| Ronald Blue Trust, Inc. | 160 | 0.00% | $73 | – | 0.00% |
| Kozak & Associates, Inc. | 49 | 0.00% | $24 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 23 | 1M | 2.6% | 3 / 3 | 4 / 4 | 0M | 1M |
| Q1 2026 | 24 | 2M | 9.1% | 8 / 3 | 2 / 2 | 2M | 0M |
| Q4 2025 | 19 | 1M | 3.3% | 1 / 6 | 3 / 5 | 0M | 0M |
| Q3 2025 | 23 | 1M | 3.4% | 7 / 4 | 5 / 3 | 0M | 0M |
| Q2 2025 | 19 | 0M | 2.0% | 4 / 5 | 2 / 5 | 0M | 0M |
| Q1 2025 | 21 | 0M | 1.7% | 6 / 8 | 1 / 4 | 0M | 0M |
| Q4 2024 | 20 | 0M | 2.3% | 2 / 4 | 2 / 5 | 0M | 0M |
| Q3 2024 | 23 | 0M | 1.2% | 6 / 5 | 3 / 2 | 0M | 0M |
| Q2 2024 | 19 | 0M | 0.9% | 5 / 3 | 2 / 2 | 0M | 0M |
| Q1 2024 | 16 | 0M | 0.7% | 3 / 4 | 1 / 3 | 0M | 0M |
| Q4 2023 | 17 | 0M | 1.3% | 17 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held VVOS in Q2 2026, 44% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VVOS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 60,769 | 0.30% | $42.54K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 60,629 | 0.30% | $27.56K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 12,072 | 0.06% | $8.45K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 8,350 | 0.04% | $5.85K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -4,300 | -0.02% | -$1.95K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ronald Kirk Huntsman | Chief Executive Officer, Director | 158,971 | 0.79% | Sep 18, 2026 |
| Bradford K. Amman | Principal Accounting Officer | 250,080 | 1.24% | Aug 26, 2026 |
| Anja B. Krammer | Director | – | – | Oct 27, 2026 |
| Mark F. Lindsay | Director | – | – | Oct 26, 2026 |
| Ralph Elias Green | Director | – | – | Oct 26, 2026 |
| Gregg C. Johnson | Director | 3,997 | 0.02% | Sep 18, 2026 |
| Leonard J. Sokolow | Director | – | – | Sep 18, 2026 |
| Investors 4 LLC V-Co | 10% owner | – | – | Jul 15, 2026 |
| Michael C. Skaff | 10% owner | 1,342,498 | 6.67% | Jul 15, 2026 |
| Investors 3 LLC V-Co | 10% owner | 2,398,402 | 11.92% | Apr 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bradford K. Amman Principal Accounting Officer | Jul 31, 2026 | Award | +250,000 | $0.41 | $102.50K | 250,080 |
| Ronald Kirk Huntsman Chief Executive Officer, Director | Jun 30, 2026 | Other | +85,910 | $0.58 | $49.83K | 85,910 |
| Investors 3 LLC V-Co 10% owner | Mar 31, 2026 | Buy | +1,044,777 | $1.34 | $1.40M | 1,044,777 |
| Investors 3 LLC V-Co 10% owner | Mar 31, 2026 | Buy | +308,848 | $1.34 | $413.86K | 1,353,625 |
| Ronald Kirk Huntsman Chief Executive Officer, Director | Jun 20, 2023 | Buy | +14,000 | $0.53 | $7.42K | 86,521 |
| Ronald Kirk Huntsman Chief Executive Officer, Director | Jun 16, 2023 | Buy | +10,000 | $0.54 | $5.40K | 67,521 |
| Ronald Kirk Huntsman Chief Executive Officer, Director | Jun 16, 2023 | Buy | +5,000 | $0.53 | $2.65K | 72,521 |
| Ronald Kirk Huntsman Chief Executive Officer, Director | Jun 15, 2023 | Buy | +21 | $0.50 | $11 | 57,521 |
| Ronald Kirk Huntsman Chief Executive Officer, Director | Jun 14, 2023 | Buy | +10,000 | $0.49 | $4.90K | 57,500 |
| Ronald Kirk Huntsman Chief Executive Officer, Director, 10% owner | Dec 23, 2022 | Buy | +20,000 | $0.50 | $10.00K | 47,500 |
| Ronald Kirk Huntsman Chief Executive Officer, Director, 10% owner | Jun 1, 2022 | Buy | +4,000 | $1.83 | $7.32K | 27,500 |
| Ronald Kirk Huntsman Chief Executive Officer, Director, 10% owner | May 31, 2022 | Buy | +8,000 | $2.03 | $16.24K | 23,500 |
| Ronald Kirk Huntsman Chief Executive Officer, Director | Sep 21, 2021 | Buy | +5,000 | $4.31 | $21.55K | 15,500 |
| Ronald Kirk Huntsman Chief Executive Officer, Director | Aug 17, 2021 | Buy | +5,000 | $3.00 | $15.00K | 10,500 |
| Bradford K. Amman Chief Financial Officer | May 25, 2021 | Buy | +1,000 | $5.29 | $5.29K | 2,000 |
| Ronald Kirk Huntsman Chief Executive Officer, Director | May 25, 2021 | Buy | +4,000 | $5.38 | $21.52K | 5,500 |
| Bradford K. Amman Chief Financial Officer | Dec 24, 2020 | Buy | +1,000 | $7.38 | $7.38K | 1,000 |
| Ronald Kirk Huntsman Chief Executive Officer, Director, 10% owner | Dec 23, 2020 | Buy | +1,000 | $7.27 | $7.27K | 1,500 |
| Ronald Kirk Huntsman Chief Executive Officer, Director, 10% owner | Dec 11, 2020 | Buy | +500 | $8.50 | $4.25K | 500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vivos Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 11,976,326 shares on Sep 1, 2026 over the last 90 days.
See a number that looks wrong?